XBIO
Xenetic Biosciences, Inc.
Set alert
- YTD
- -5.53%
- 1 year
- -37.69%
- Open
- 2.14
- Prev close
- 2.12
- Mkt cap
- 4.80M
- Vol
- 32.62K
- Avg vol
- 90.07K
- EPS
- -1.15
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.95
- High
- 2.15
- Forward P/E
- -6.20
- Beta
- 2.26
- Short ratio
- 0.77
- Inst. own
- 2.10%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.99
- 200-d avg
- 4.00
- 1y target
- 0.00
Key statistics
- Market cap
- 6.31M
- Enterprise value
- -927.76K
- Trailing P/E
- 0.00
- Forward P/E
- -6.20
- PEG ratio
- 0.00
- Price / sales
- 2.50
- Price / book
- 0.64
- EPS (TTM)
- -2.66
- Beta
- 2.26
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -186.33%
- Revenue (TTM)
- 2.52M
- Revenue growth
- 11.60%
- Free cash flow
- -1.55M
- Total cash
- 7.30M
- Total debt
- 0
- Return on equity
- -48.60%
- Shares outstanding
- 1.54M
- Short % of float
- 1.02%
- 50-day average
- 3.99
- 200-day average
- 4.00
Analyst view
Consensus: none
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.14 | -0.28 | -0.14 | -100.00% |
| Aug 13, 2024 | Jun 1, 2024 | -0.83 | -0.83 | 0.00 | 0.00% |
| May 9, 2024 | Mar 1, 2024 | -0.79 | -0.78 | +0.01 | +1.27% |
| Mar 21, 2024 | Dec 1, 2023 | -0.87 | -0.77 | +0.10 | +11.49% |
| Nov 10, 2023 | Sep 1, 2023 | -1.12 | -0.69 | +0.43 | +38.39% |
| Aug 11, 2023 | Jun 1, 2023 | -1.13 | -0.69 | +0.44 | +38.94% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Nov 22, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Aug 20, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| May 16, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
About Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- xeneticbio.com
News
- Xenetic Biosciences (NASDAQ:XBIO) versus Oncobiologics (NASDAQ:OTLK) Critical Analysis
- Xenetic Biosciences Announces Its Collaboration Partner PeriNess Doses First Participant In Clinical Trial Of Systemic Recombinant Human DNase To Treat Large B-Cell Lymphoma In Israel
- Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Financial Contrast: Xenetic Biosciences (NASDAQ:XBIO) & Allarity Therapeutics (NASDAQ:ALLR)
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Crude Oil Down Over 3%; US Business Inventories Surge In July
- Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks Transcript
- Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition
Your note
Sign in to keep a note on XBIO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sachetta, LLC | 1.13% | 17,371 | 71.05K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.03% | 15,850 | 64.83K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.77% | 11,889 | 48.63K | Sep 29, 2024 |
| JTC Employer Solutions Trusteee Ltd | 0.18% | 2,700 | 11.04K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.04% | 692 | 2.83K | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.01% | 200 | 818 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.64% | 9,797 | 40.07K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.49% | 7,632 | 31.21K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.13% | 2,070 | 8.47K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 1,823 | 7.46K | Oct 30, 2024 |